ArticleJournal of hepato-biliary-pancreatic sciences2026
Reframing Post-Hepatectomy Liver Failure as a Determinant of Post-Recurrence Survival in HCC.
Article in Journal of hepato-biliary-pancreatic sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPost-hepatectomy liver failure (PHLF) is traditionally considered a transient perioperative complication with limited long-term consequences, yet its long-term oncologic implications in hepatocellular carcinoma (HCC) remain unclear.
methodsPatients undergoing primary hepatectomy for HCC between 2007 and 2018 were analyzed. To ensure reliable assessment of recurrence and post-recurrence survival, follow-up was continued through 2023. Associations between PHLF and overall survival (OS), time to recurrence (TTR), and survival after recurrence (SAR) were assessed. Propensity score matching (PSM) analysis controlled for baseline differences.
resultsPHLF ≥ grade B occurred in 59 patients (14.6%). It was significantly associated with worse OS (45.6 vs. 109.7 months, p < 0.001) and SAR (21.5 vs. 55.9 months, p < 0.001), but not TTR. After PSM, these associations persisted. At recurrence, patients with PHLF had worse ALBI scores (-1.92 vs. -2.57, p < 0.001) and lower rates of re-resection for recurrent disease (6.9% vs. 29.3%, p = 0.026), even after PSM.
conclusionsPHLF ≥ grade B compromised hepatic reserve at recurrence and limiting curative salvage therapy, leading to impaired SAR and OS. Prevention of PHLF should be prioritized not only to reduce perioperative risk but also to optimize long-term oncologic outcomes in HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.